[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"elderly\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:elderly":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,65,0,25,[9,46,81,123,153,174,196,226,239,263,295,326,354,382,422,453,476,499,524,557,584,607,632,657,690],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053907","hybrid-group-singing-100053907",false,"NCT07355192","Hybrid Group Singing","Group Singing (Hybrid Format) or Solo Singing in Older Adults With Coronary Artery Disease: A Feasibility Study","Inclusion Criteria:\n\n* history of coronary artery disease (defined as having at least 1 of the following: myocardial infarction, coronary stent, PCI, CABG, coronary stenosis at least 50%, or coronary artery calcification score at least 300 Agatston units)\n\nExclusion Criteria:\n\n* Parkinson's disease or tremor\n* upper arm fistula\n* fingernail onychomycosis\n* pregnancy\n* current tobacco use\n* current illicit drug use\n* current excessive alcohol use (defined as more than 14 drinks\u002Fweek for women, more than 28 drinks\u002Fweek for men)\n* unstable CAD (active symptoms of chest discomfort)\n* supplemental oxygen use\n* more than mild cognitive impairment (as documented in the medical record by patient's treatment teams)\n* inability to follow study procedures\n* non-English speaking","ALL","55 Years","89 Years",{"count":21,"type":22},32,"ESTIMATED","INTERVENTIONAL",[25],"NA","The overall objective of the planned future clinical trial is to test the investigator's central hypothesis that habitual singing over several weeks, similar to habitual exercise, will lead to sustained and favorable vascular adaptation, thereby lowering cardiovascular disease (CVD) risk. The overall objective of this study is to refine and protocolize the singing interventions and test the feasibility of the future trial design. The investigative team has previously studied solo singing. Collective singing, as in a choir or small group, is associated with a positive sense of social inclusion, well-being, and improved mood, including in older adults.",[28,29],"Coronary Artery Disease","Elderly",[31,32],"group singing","individual singing","RECRUITING","2026-07-09",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-05-11",{"date":41,"type":22},"2028-02",{"name":43,"class":44},"Medical College of Wisconsin","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":45},"100498084","effectiveness-of-a-joint-general-practitioner-pharmacist-intervention-on-benzodiazepine-deprescribing-in-the-elderly-100498084","NCT05765656","Effectiveness of a Joint General Practitioner-Pharmacist Intervention on Benzodiazepine Deprescribing in the Elderly","Evaluation of the Effectiveness of a Joint General Practitioner-Pharmacist Intervention on the Implementation of Benzodiazepine Deprescribing in the Elderly (BESTOPH-MG Trial): Protocol for a Cluster-randomized Controlled Trial","BESTOPH-MG","Inclusion Criteria:\n\n* outpatients aged 65 and over\n* followed by the general practitioner and the pharmacist of the GP-PO pair\n* having a prescription for an anxiolytic or hypnotic BZDR prescribed at least 4 times in the past year\n* the last prescription being less than 3 months old\n* having been dispensed monthly during the last 3 months\n* affiliated to a social security scheme\n* and having given consent to participate in the research.\n\nExclusion Criteria:\n\n* patients living in an institution\n* participating in a clinical trial\n* with epilepsy\n* active depression\n* uncontrolled mental disorders\n* unable to participate in an interview or answer a questionnaire (demented, non-French speaking, illiterate, deaf, ...)\n* under guardianship\n* with a dystonic syndrome\n* and patients who are not sufficiently autonomous to carry out the steps inherent in the study","65 Years",{"count":56,"type":22},400,[25],"Benzodiazepines or related drug (BZDR) are consumed for hypnotic or anxiolytic purposes in most cases. The consequences of BZDR are multiple with an increased risk of daytime sedation, balance disorders leading to falls and fractures, cognitive disorders, road accidents and dementia. Given their comorbidities, physiological changes, and multiple medications, the elderly are more at risk of suffering from BZDR adverse events.\n\nInterprofessional collaboration has shown efficacy in improving prescribing appropriateness and may affect patients outcomes positively. Morever, motivational interviews (MI) may reduce the extent of substance abuse compared to no intervention.",[60,61,62,29,63,64],"Primary Care","Health Plan Implementation","Benzodiazepine Dependence","Anxiety","Deprescribing",[66,67,68,69,70,71],"Primary care","collaborative practice","health plan implementation","deprescribing","benzodiazepine","elderly","2026-06-19",{"date":74,"type":37},"2026-06-24",{"date":76,"type":37},"2023-10-16",{"date":78,"type":22},"2027-02-16",{"name":80,"class":44},"Nantes University Hospital",{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":101,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":45},"100376320","impact-of-positive-airway-pressure-therapy-on-clinical-outcomes-in-older-veterans-with-chronic-obstructive-pulmonary-disease-and-comorbid-obstructive-sleep-apnea-overlap-syndrome-100376320","NCT04179981","Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)","Inclusion Criteria:\n\n* OSA with moderate-to-severe disease, AHI 20 per hour by in-lab polysomnography with concomitant moderate-severe COPD based on pulmonary function tests (PFTS) and with past significant history (\\>10 pack-years) of smoking\n* Male or female gender\n* Age greater than or equal to 60 years\n* Stable treatment regimen for COPD\n\nExclusion Criteria:\n\n* Current or prior treatment with PAP or oral appliance\n* Central sleep apnea defined as central apnea index \\>5 per hour and comprising 50% of AHI\n* Known primary neuromuscular diseases\n* Disorders that may impact cognitive function including:\n\n  * neurodegenerative disorders\n  * traumatic brain injury\n* untreated PTSD and\u002For history of learning disability\n* Medicines that may cause or alter sleepiness: sedative hypnotics, or stimulants as these may alter the results\n* Patient is actively suicidal due to depression, unstable mental health condition\n* Epworth sleepiness score \\>16 (severe sleepiness) or a near-miss or prior automobile accident due to sleepiness within the past 12 months\n* Narcolepsy is the primary sleep disorder, with requirement of stimulant medications\n* Employed as a commercial driver or operating heavy machinery\n* On long-term oxygen therapy prior to start of study, more than 12 hr\u002Fday\n* Patients is unable to use either a nasal or face mask (e.g., facial trauma, claustrophobia)\n* Consumption of \\>3 alcoholic beverages per day or current use of some illicit drugs, as these may contribute to cognitive deficits\n* Patients who cannot give informed consent\n* Patients receiving hospice care\n* Pregnant women due to unknown risks","60 Years",{"count":89,"type":22},668,[25],"Obstructive sleep apnea (OSA) and Chronic Obstructive Pulmonary Disease (COPD) are highly prevalent chronic respiratory diseases in the Veteran population. OSA co-occurring with COPD, known as Overlap Syndrome (OVS), is a complex chronic medical condition associated with grave consequences. OVS is highly prevalent in Veterans. Veterans with OVS may be at increased risk for cognitive deficits, poor sleep quality as well as a reduced quality of life (QoL). The overall objective is to study the effects of positive airway pressure therapy on clinical outcomes in patients with OVS.",[93,94,95,96,97,98,99,29,100],"Sleep Apnea Syndrome","Obstructive Sleep Apnea","COPD","Overlap Syndrome","Quality of Life","Neurocognitive Function","Sleepiness","Positive Airway Pressure",[102,103,104,105,106,107,108,109,110,111,112],"Apnea","Sleep Apnea Syndromes","Sleep Apnea, Obstructive","Nervous System Diseases","Respiration Disorders","Respiratory Tract Diseases","Signs and Symptoms, Respiratory","positive airway pressure","cognitive function","quality of life","sleepiness","2026-06-03",{"date":115,"type":37},"2026-06-05",{"date":117,"type":37},"2020-12-01",{"date":119,"type":22},"2027-12-31",{"name":121,"class":122},"VA Office of Research and Development","FED",{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":130,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":131,"targetDuration":133,"studyType":134,"phases":4,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":45},"100640366","validity-and-reliability-of-the-turkish-form-of-the-enjoyment-of-physical-activity-scale-8-in-geriatrics-with-minimal-cognitive-impairment-100640366","NCT07588685","Validity and Reliability of the Turkish Form of the Enjoyment of Physical Activity Scale-8 in Geriatrics With Minimal Cognitive Impairment","Validity and Reliability of the Turkish Form of the Enjoyment of Physical Activity Scale-8 (PACES-8) in Geriatric Individuals With Minimal Cognitive Impairment","Inclusion Criteria:\n\n* Being 65 years of age or older,\n* Having a diagnosis of Minimal Cognitive Impairment (MCI),\n* Having a Standardized Mini Mental Test (SMMT) score between 24 and 27 (mild cognitive impairment level),\n* Being largely independent in daily living activities (absence of functional dependency),\n* Being able to mobilize independently,\n* Having the communication level to understand and answer the survey questions,\n* Volunteering to participate in the study and providing written informed consent.\n\nExclusion Criteria:\n\n* Diagnosis of dementia or advanced cognitive impairment,\n* Acute medical conditions that prevent participation in physical activity,\n* Severe vision or hearing loss,\n* Presence of neurological or psychiatric disorders that prevent completion of questionnaire forms,\n* Serious neurological event within the last 6 months (stroke, traumatic brain injury, etc.).",true,{"count":132,"type":22},100,"1 Week","OBSERVATIONAL","The main objective of this study is to examine the validity and reliability of the Turkish form of the Enjoyment of Physical Activity Scale-8 (PACES-8) in individuals aged 65 and over with Minimal Cognitive Impairment (MCI).",[137,29,138],"Geriatric","Cognitive Abnormality",[140,141,142,71],"physical activity","enjoyment","cognitive impairment","NOT_YET_RECRUITING","2026-05-14",{"date":146,"type":37},"2026-05-18",{"date":148,"type":22},"2026-05-15",{"date":150,"type":22},"2026-08-01",{"name":152,"class":44},"Istanbul University - Cerrahpasa",{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":130,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":159,"targetDuration":133,"studyType":134,"phases":4,"briefSummary":161,"conditions":162,"keywords":163,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":173,"locationsCount":45},"100636222","validity-and-reliability-of-the-exercise-related-health-beliefs-attitude-scale-in-geriatric-individuals-100636222","NCT07562880","Validity and Reliability of the Exercise-Related Health Beliefs Attitude Scale in Geriatric Individuals","Inclusion Criteria:\n\n* Being 65 years of age or older,\n* Volunteering to participate in the research\n* Not having a disease that affects cognitive function\n* Being able to understand the questions asked by the researchers\n* Volunteering\n\nExclusion Criteria:\n\n* Severe vision\u002Fhearing loss,\n* Having cognitive diseases such as dementia, Alzheimer's, etc.\n* Inability to walk\n* Not being a volunteer",{"count":160,"type":22},200,"The main purpose of this research is to test the validity and reliability of the \"Exercise Health Beliefs Attitude Scale\" (EYSİTÖ), developed by Caz, Paktaş and Yazıcı (2023) for adult individuals, in geriatric individuals aged 65 and over.",[137,29],[164,165,166,71],"exercise behavior","pyhsical activity","motivatıon","2026-05-09",{"date":169,"type":37},"2026-05-13",{"date":171,"type":22},"2026-05-05",{"date":150,"type":22},{"name":152,"class":44},{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":130,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":181,"targetDuration":183,"studyType":134,"phases":4,"briefSummary":184,"conditions":185,"keywords":186,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":195,"locationsCount":45},"100636220","comparison-of-hand-grip-strength-in-different-shoulder-positions-in-geriatric-individuals-position-dependent-strength-analysis-100636220","NCT07562854","Comparison of Hand Grip Strength in Different Shoulder Positions in Geriatric Individuals: Position-Dependent Strength Analysis","Comparison of Hand Grip Strength in Different Shoulder Positions in Geriatric Individuals: Position-Dependent Strength Analysis - A Cross-Sectional Analytical Study With Repeated Measurements","Inclusion Criteria:\n\n* Being 65 years of age or older\n* Being an independent volunteer living in the community\n* Being able to actively use the upper extremities\n* Having the cognitive level to understand and follow the measurement instructions\n* Providing written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Presence of severe shoulder pain or rotator cuff pathology\n* Loss of upper extremity function due to rheumatological disease\n* Presence of significant visual or vestibular impairment that may affect measurements\n* Presence of another systemic or musculoskeletal disease that may prevent the safe and accurate completion of tests\n* History of upper extremity surgery or fracture within the last 6 months\n* Failure to provide informed consent",{"count":182,"type":22},40,"1 Day","The aim of this study is to examine the relationship between hand grip strength, measured in different shoulder positions, and upper extremity muscle strength, and to reveal the clinical significance of position-dependent strength variation.",[137,29],[187,188,189,190],"muscle strenght","hand grip strength","geriatrics","upper extremity muscle strength",{"date":169,"type":37},{"date":193,"type":22},"2026-05-02",{"date":150,"type":22},{"name":152,"class":44},{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":17,"minAge":203,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":23,"phases":206,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":225},"100589989","score-study-comparing-surgery-and-rigid-collar-treatment-for-odontoid-fractures-in-adults-over-70-100589989","NCT06961578","SCORE Study: Comparing Surgery and Rigid Collar Treatment for Odontoid Fractures in Adults Over 70","Surgical Versus Conservative Treatment of Odontoid Fractures in the Elderly: A Randomised Controlled Clinical Study (SCORE)","Inclusion Criteria:\n\n* At least 70 years old\n* Acute unstable OFs (types II, III as classified by Anderson and d'Alonzo, and atypical)\n* Less than two weeks post injury\n* Written informed consent\n\nExclusion Criteria:\n\n* Previous treatment for odontoid fracture\n* Concomitant fractures of the subaxial cervical spine necessitating surgery\n* Significant comorbidity resulting in inoperability of the patient: i.e. ASA score \\> 4\n* Neurological compromise due to displaced fracture","70 Years",{"count":205,"type":22},322,[25],"The goal of this clinical trial is to compare two treatment options-surgery or rigid collar bracing-for unstable neck fractures (odontoid fractures) in adults aged 70 years and older. These fractures are common in older adults and can significantly impact mobility, independence, and quality of life. There is currently no clear evidence to determine which treatment is better for this population. The main questions it aims to answer are:\n\n* Does surgery or conservative collar treatment lead to better improvement in daily living, measured by the Barthel Index, after 12 weeks?\n* What are the differences in pain, disability, and quality of life between the two treatments?\n\nThe study team will compare patients who receive surgical stabilization with those who are treated with a rigid cervical collar to see which approach supports better functional outcomes and healing.\n\nParticipants will:\n\n* be randomly assigned to either surgery (posterior C1-C2 screw-rod fixation) or conservative collar treatment\n* attend study visits at 12 weeks and 6 months\n* complete questionnaires on daily functioning, pain, and quality of life\n* undergo CT scans and other medical assessments\n* record collar use (for conservative group) in a diary\n* be monitored for any complications or changes in treatment (including crossover to surgery if needed)\n\nThe study aims to include 322 participants to provide evidence on which treatment helps older adults recover better from odontoid fractures with fewer complications and improved quality of life.",[209,29],"Odontoid Fracture",[211,212,213,214,215,216],"Odontoid fracture","C2 fracture","atlantoaxial instability","atlantoaxial fusion","Barthel Index","functional outcome",{"date":218,"type":37},"2026-05-06",{"date":220,"type":37},"2025-08-13",{"date":222,"type":22},"2028-06-01",{"name":224,"class":44},"Technical University of Munich",16,{"id":227,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":228,"targetDuration":4,"studyType":23,"phases":229,"briefSummary":26,"conditions":230,"keywords":231,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":238,"locationsCount":45},"100620251",{"count":21,"type":22},[25],[28,29],[31,32],"2026-04-28",{"date":234,"type":37},"2026-05-04",{"date":236,"type":22},"2026-04",{"date":41,"type":22},{"name":43,"class":44},{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":130,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":246,"targetDuration":248,"studyType":134,"phases":4,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":45},"100636224","validity-and-reliability-of-the-exergame-enjoyment-questionnaire-eeq-in-turkish-100636224","NCT07562906","Validity and Reliability of the Exergame Enjoyment Questionnaire (EEQ) in Turkish","Validity and Reliability of the Exergame Enjoyment Questionnaire (EEQ) in a Geriatric Population in Turkish","Inclusion Criteria:\n\n* Being 65 years of age or older\n* Having participated in an exergaming application at least once before\n* Not having a physical, sensory or cognitive disability that would prevent participation in the exergaming application\n* Agreeing to participate voluntarily and providing informed consent\n\nExclusion Criteria:\n\n1. Individuals with active neurological, vestibular, or psychiatric disorders\n2. Individuals diagnosed with moderate or severe cognitive impairment (MMSE \\\u003C 24 and\u002For MoCA \\\u003C 21)\n3. Individuals with severe hearing or vision loss\n4. Individuals who are physically unable to participate in exergaming due to cardiopulmonary or orthopedic reasons\n5. Individuals with no prior exergaming experience\n6. Individuals who experience significant communication difficulties\n7. Participants who do not sign the voluntary consent form",{"count":247,"type":22},46,"2 Weeks","The aim of this research is to adapt the Exergame Enjoyment Questionnaire (EEQ) into Turkish and to evaluate its suitability for the Turkish elderly population through validity and reliability analyses. After the cultural adaptation process is completed, the construct validity of the scale will be evaluated using exploratory and confirmatory factor analyses; its reliability will be assessed through internal consistency coefficients (Cronbach's alpha) and test-retest reliability over time (ICC). Accordingly, the study aims to provide a valid and reliable assessment tool for clinicians and researchers who wish to evaluate individual experiences in exergaming-based interventions.",[137,29],[252,253,189,254],"exercise","exercise enjoyment","validation","2026-04-25",{"date":257,"type":37},"2026-05-01",{"date":259,"type":22},"2026-04-30",{"date":261,"type":22},"2026-09-30",{"name":152,"class":44},{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":130,"sex":17,"minAge":54,"maxAge":270,"enrollmentInfo":271,"targetDuration":4,"studyType":23,"phases":273,"briefSummary":275,"conditions":276,"keywords":281,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":290,"leadSponsor":292,"locationsCount":294},"100633180","phase-4-impact-of-esketamine-on-delayed-neurocognitive-recovery-in-older-patients-100633180","NCT07523334","Impact of Esketamine on Delayed Neurocognitive Recovery in Older Patients","Impact of Esketamine on Delayed Neurocognitive Recovery in Older Patients Undergoing Non-cardiac Surgery: a Two-center, Dose-exploring Pilot Trial","Inclusion Criteria:\n\n1. Aged \\>=65 but \\\u003C= 90 years;\n2. Scheduled to undergo non-cardiac surgery with an expected duration of \\>= 2 hours under general anesthesia;\n3. Requiring patient-controlled intravenous analgesia (PCIA) after surgery.\n\nExclusion Criteria:\n\n1. Unable to communicate preoperatively due to visual or auditory impairment, language barrier, or severe dementia;\n2. Comorbid with schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis;\n3. Traumatic brain injury or neurosurgery;\n4. Severe hepatic dysfunction (Child-Pugh Class C), severe renal dysfunction (receiving dialysis preoperatively), or American Society of Anesthesiologists physical status classification \\>= Ⅳ;\n5. Expected admission to the Intensive Care Unit with endotracheal intubation after surgery;\n6. Anaphylaxis to esketamine;\n7. Participation in other clinical studies, or any other conditions that are considered unsuitable to be involved in the study.","90 Years",{"count":272,"type":22},120,[274],"PHASE4","Esketamine is frequently used during the perioperative period for supplemental analgesia. Small sample size trials showed that subanesthetic dose esketamine may decrease postoperative neurocognitive complications. However, conflicting results exist and optimal dose of esketamine remains to be determined. This dose-exploring pilot trial is designed to evaluate the safety and efficacy of three different perioperative esketamine dosing regimens in older patients undergoing major non-cardiac surgery. The primary purpose is to explore the optimal dosing strategy that produce maximal neurocognitive benefits with minimal adverse neuropsychiatric symptoms.",[29,277,278,279,280],"Noncardiac Surgery","Delayed Neurocognitive Recovery","Postoperative Delirium","Esketamine",[282,283,284,285,280],"Older patients","Noncardiac surgery","Delayed neurocognitive recovery","Postoperative delirium","2026-04-09",{"date":288,"type":37},"2026-04-14",{"date":236,"type":22},{"date":291,"type":22},"2026-12",{"name":293,"class":44},"Peking University First Hospital",2,{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":130,"sex":17,"minAge":303,"maxAge":304,"enrollmentInfo":305,"targetDuration":4,"studyType":23,"phases":307,"briefSummary":308,"conditions":309,"keywords":312,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":45},"100633015","effect-of-vegetarien-diet-on-protein-digestibility-in-young-and-elderly-volunteers-100633015","NCT07521189","Effect of Vegetarien Diet on Protein Digestibility in Young and Elderly Volunteers","Effect of a Vegetarian Diet on the Bioavailability of Amino Acids From Plant Protein in Healthy Young and Elderly Volunteers (VEGAA)","VEGAA","Inclusion Criteria:\n\n* Normal weight or overweight (18 \\\u003C BMI \\\u003C 30 kg·m-²)\n* Male or female\n* Aged 18-23 years (young groups) or 65-75 years (older groups)\n* Following an omnivorous diet (regular consumption of meat products, with meat intake \\> 3 times\u002Fweek and \\> 70% of protein intake from animal sources) or vegetarian diet (exclusion of meat and fish\u002Fseafood, with \\> 70% of protein intake from plant sources)\n* In good general health (WHO = 0)\n* Affiliated with a social security system\n* Free and informed consent, provided in writing after receiving the information required by the Public Health Code\n\nExclusion Criteria:\n\n* Adults under legal protection or unable to give informed consent (e.g., under guardianship, trusteeship, or legal protection)\n* Any known food allergy\n* Positive serology for HBsAg, anti-HBc, HCV, or HIV\n* Anemia: hemoglobin level \\\u003C 13 g\u002FdL in men and \\\u003C 12 g\u002FdL in women\n* Pregnant women or those who may be pregnant (based on a positive urine pregnancy test at inclusion)\n* Excessive alcohol consumption (\\> 2 drinks\u002Fday). Harmful alcohol use will be assessed by the investigator at inclusion.\n* Hypertension, diabetes, gastrointestinal, liver or kidney diseases, or severe heart disease. These conditions will be assessed by the investigator based on standard clinical evaluation and participants' self-reports at inclusion.\n* Hypertension: significant arterial hypertension according to the investigator, or systolic blood pressure ≥ 140 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg at inclusion.\n* Diabetes: type 1 or type 2 diabetes, or fasting blood glucose \\> 1.25 g\u002FL.\n* Gastrointestinal disease: clinically significant gastrointestinal disorders (bleeding, vomiting, constipation\u002Fdiarrhea grade \\> 1) as judged by the investigator, any inflammatory bowel disease, or acute gastroenteritis in the month prior to the intervention.\n* Liver disease: any significant hepatic disorder according to the investigator, or ASAT\u002FALAT \\> 2.5 times the upper normal limit.\n* High-level athletes (\\> 8 hours of training per week)\n* Blood donation within 8 weeks prior to study start\n* Absence of free, informed, written consent after receiving the information required by the Public Health Code\n* Not affiliated with a social security system","18 Years","75 Years",{"count":306,"type":22},48,[25],"Plant proteins are usually less digestible than animal proteins, but they may benefit gut health through effects on the microbiome. The long-term impact of diets rich in plant products on protein digestion and metabolism is still unknown, especially in older adults with higher protein needs. This study aims to compare the digestion and use of pea proteins in young and older adults, both vegetarians and omnivores. Volunteers are divided into four groups: young omnivores, young vegetarians, older omnivores, and older vegetarians. They take part in two clinical investigation days. On the first day, nitrogen retention and protein metabolism is measured after consumption of a pea-based meal. On the second day, amino acid digestibility of pea is evaluated. These results will provide valuable data on how plant proteins are digested and metabolized depending on age and diet. They will also help determine whether aging reduces the availability of plant proteins. This knowledge is important to support nutritional strategies for populations with specific protein needs, such as older adults.",[310,29,311],"Vegetarian Diet","Young Healthy Adults",[313,314,29,315,316,317],"Amino acid bioavailability","Vegetarian diet","Plant protein","Protein utilization","Isotopic method","2026-04-07",{"date":286,"type":37},{"date":321,"type":37},"2025-10-22",{"date":323,"type":22},"2026-12-31",{"name":325,"class":44},"Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement",{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":17,"minAge":87,"maxAge":203,"enrollmentInfo":333,"targetDuration":4,"studyType":23,"phases":335,"briefSummary":336,"conditions":337,"keywords":341,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":45},"100632103","mdt-based-umbrella-decision-model-for-geriatric-lung-cancer-patients-100632103","NCT07509333","MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients","Establishment and Validation of a Multidisciplinary Team (MDT)-Based Umbrella Decision-making and Treatment Model for Geriatric Lung Cancer Patients","Inclusion Criteria:\n\n1. Age 60 to 90 years.\n2. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC).\n3. Clinical stage I-IV (according to the 9th edition of the IASLC TNM staging system).\n4. ECOG Performance Status 0-2.\n5. Estimated life expectancy ≥ 3 months.\n6. Able to tolerate baseline examinations (including CT, MRI, pulmonary function tests) and at least one planned treatment modality (surgery, ablation, SBRT, etc.) as assessed by the investigator.\n7. Patients or their legal representatives provide written informed consent and commit to completing the full follow-up schedule (including questionnaires and functional assessments).\n8. Other conditions deemed suitable by the investigator.\n\nExclusion Criteria:\n\n1. History of other primary malignancies within the past 5 years (except non-melanoma skin cancer or carcinoma in situ of the cervix).\n2. Unclear pathological diagnosis (no definite histologic or cytologic evidence) or post-enrollment pathological review excludes lung cancer.\n3. Severe psychiatric disorders (e.g., Alzheimer's disease, schizophrenia) or cognitive impairment (MMSE score \\\u003C 20) that interferes with questionnaire completion or treatment decision-making communication.\n4. Contraindications to study-related examinations or treatments:\n\n   4.1Known contraindication to iodine-based contrast agents or MRI (e.g., incompatible metallic implants).\n\n   4.2Known severe allergy to any of the essential therapeutic agents (e.g., chemotherapy, targeted drugs) involved in the study.\n5. Severe organ dysfunction (e.g., Child-Pugh class C cirrhosis, end-stage renal disease without dialysis) that precludes tolerability of baseline examinations or any treatment.\n6. No fixed residential address or effective contact information, or family members refuse to assist with follow-up, leading to an estimated follow-up dropout risk \\> 50%.\n7. Concurrent participation in another interventional clinical trial for lung cancer (observational studies are allowed).\n8. Any other condition that, in the opinion of the investigator, makes the patient unsuitable for study participation.",{"count":334,"type":22},2000,[25],"This is a single-center, prospective, single-arm interventional study with historical control, designed to evaluate the clinical value of a multidisciplinary team (MDT)-based decision-making umbrella decision model in elderly patients with lung cancer. A total of 2,000 patients aged 60-90 years with newly diagnosed non-small cell or small cell lung cancer will be enrolled. Each patient will undergo comprehensive geriatric assessment and receive an individualized treatment plan formulated by an MDT comprising thoracic surgeons, geriatricians, oncologists, pulmonologists, rehabilitation therapists, and radiologists. Treatment options include surgery, ablation, stereotactic body radiotherapy (SBRT), neoadjuvant immunochemotherapy, targeted therapy, and best supportive care. The primary outcome is 3-year progression-free survival (PFS). Secondary outcomes include overall survival, objective response rate, quality of life (EORTC QLQ-LC43), incidence of adverse events (CTCAE v5.0), and healthcare economics. Historical controls (2014-2024) will be extracted from hospital records and matched using propensity score matching. The study aims to establish a standardized MDT pathway to improve treatment outcomes and reduce risks in the geriatric lung cancer population.",[338,339,340,29],"Lung Neoplasms","Carcinoma, Non-Small-Cell Lung","Small Cell Lung Carcinoma",[342,29,137,343,344],"Lung cancer","Multidisciplinary team","Umbrella trial","2026-03-28",{"date":347,"type":37},"2026-04-03",{"date":349,"type":37},"2025-12-01",{"date":351,"type":22},"2030-10-31",{"name":353,"class":44},"West China Hospital",{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":130,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":361,"targetDuration":363,"studyType":134,"phases":4,"briefSummary":364,"conditions":365,"keywords":370,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":45},"100617141","elderly-patients-undergoing-surgery-during-perioperative-period-100617141","NCT07314762","Elderly Patients Undergoing Surgery During Perioperative Period","Elderly Patients Undergoing Surgery During Perioperative Period: a Prospective Cohort Study","Inclusion Criteria:\n\n1\\) Surgical patients aged 65 or above or non-surgical subjects aged 65 or above. 2) Agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n1）Refused to participate in the study.",{"count":362,"type":22},1200,"1 Year","The elderly patients have poorer overall conditions and have lower tolerance to trauma, anesthesia, and surgery. Therefore, the incidence of postoperative complications is relatively higher. In non-cardiac surgeries, approximately 20% of elderly patients experience postoperative complications, and the incidence of postoperative delirium (POD) is 23.8%. This may lead to prolonged hospital stays, increased hospital costs, and affect prognosis and even mortality. The investigators plan to conduct a prospective cohort study by systematically collecting biological samples and clinical information of elderly patients during the perioperative period to explore the possible risk factors and pathogenesis of postoperative delirium and postoperative complications in elderly surgical patients, and to construct a risk prediction model for postoperative complications.",[366,29,367,368,369],"Postoperative Complications","Postoperative Delirium (POD)","Risk Prediction Model","Pathogenesis",[371,71,372],"postoperative delirium","Cohort study","2026-03-26",{"date":375,"type":37},"2026-04-01",{"date":377,"type":37},"2023-12-30",{"date":379,"type":22},"2030-12-30",{"name":381,"class":44},"Second Affiliated Hospital of Wenzhou Medical University",{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":388,"eligibilityCriteria":389,"healthyVolunteers":130,"sex":17,"minAge":303,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":23,"phases":392,"briefSummary":393,"conditions":394,"keywords":399,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":420,"locationsCount":294},"100630933","aurora-ai-based-narrative-intervention-to-support-emotional-well-being-in-clinical-and-non-clinical-populations-100630933","NCT07494110","Aurora: AI-Based Narrative Intervention to Support Emotional Well-Being in Clinical and Non-Clinical Populations","Aurora: Evaluation of an AI-Based Narrative Intervention for Emotional Well-Being, Identity Processes, and Recovery-Oriented Outcomes in Clinical and Non-Clinical Populations","Aurora","Inclusion Criteria\n\nArm 1: Healthy Adults (Single-Session Intervention)\n\nAge 18 years or older at screening.\n\nSufficient ability to read and understand Spanish to follow study instructions and complete questionnaires.\n\nAbility to engage in a brief guided interaction and complete self-report measures.\n\nAble and willing to provide written informed consent.\n\n\\---\n\nArm 2: Adults with DSM-5 Diagnosed Mental Disorder in Residential Care (4-hour Intervention)\n\nAge 18 years or older at screening.\n\nCurrently residing in a participating long-term mental health residential care facility and expected to remain there for the duration of the intervention and post-assessment period.\n\nDocumented diagnosis of a mental disorder according to DSM-5 criteria, confirmed by the treating clinician.\n\nMinimal clinical stability at baseline, defined as all of the following:\n\nClinically stable in the judgment of the treating clinician.\n\nNo requirement for acute psychiatric hospitalization or crisis intervention in the previous 4 weeks.\n\nClinical Global Impression - Improvement (CGI-I) score between 3 and 5 inclusive during the 4 weeks prior to enrollment, indicating relative clinical stability.\n\nSufficient ability to understand spoken and written Spanish to participate in study procedures.\n\nAbility to engage in guided interaction and provide feedback.\n\nAble and willing to provide informed consent; when applicable, provision of legal guardian consent plus participant assent.\n\nWillingness to participate in all study procedures.\n\n\\---\n\nArm 3: Healthy Older Adults (≥65 Years; 4-hour Intervention)\n\nAge 65 years or older at screening.\n\nNo self-reported diagnosis of a serious mental disorder (for example, psychotic disorder or bipolar disorder).\n\nSufficient ability to read and understand Spanish to participate in study procedures.\n\nAdequate cognitive and communication abilities to engage in guided interaction and complete questionnaires.\n\nAble and willing to provide written informed consent.\n\n\\---\n\nExclusion Criteria\n\nArm 1: Healthy Adults\n\nCurrent acute medical or psychiatric condition that would compromise safe participation or data validity.\n\nModerate or high acute suicide or self-harm risk at screening.\n\nSignificant cognitive, communication, or comprehension impairment that would interfere with participation.\n\nExplicit refusal to participate.\n\n\\---\n\nArm 2: Adults with DSM-5 Diagnosed Mental Disorder in Residential Care\n\nCurrent acute psychiatric decompensation requiring crisis-level care.\n\nModerate or high acute suicide or self-harm risk at screening or baseline.\n\nHigh risk of clinically significant emotional harm from autobiographical life review, defined as treating clinician judgment that narrative or reminiscence work is contraindicated due to one or more of the following:\n\nSevere clinical destabilization within the past 3 months.\n\nTrauma-related re-experiencing symptoms.\n\nMarked dissociative symptoms.\n\nInability to provide informed consent, with no legal representative available when required, or lack of participant assent when applicable.\n\nSignificant cognitive, communication, or comprehension impairment without available supports.\n\nExplicit refusal to participate.\n\nImminent discharge or transfer that would prevent completion of the intervention or post-assessment.\n\n\\---\n\nArm 3: Healthy Older Adults\n\nSelf-reported diagnosis of a serious mental disorder (for example, psychotic disorder or bipolar disorder).\n\nModerate or high acute suicide or self-harm risk at screening.\n\nCurrent acute medical or psychiatric condition that would compromise safe participation.\n\nSignificant cognitive, communication, or comprehension impairment that would interfere with participation.\n\nExplicit refusal to participate.",{"count":391,"type":22},55,[25],"Aurora is an interdisciplinary project evaluating a chatbot-mediated supportive care intervention designed to promote emotional expression, autobiographical meaning-making, identity processes, and emotional well-being through guided narrative reconstruction. The Aurora system provides a structured, person-centered storytelling process supported by generative AI and human facilitation. Under the supervision of a trained facilitator (licensed mental health professional), participants engage in guided reminiscence and storytelling sessions to co-create a personalized \"life book.\" The chatbot is not a diagnostic or treatment tool; rather, it is intended to support emotional expression, narrative reconstruction, and recovery-oriented processes. The study includes three non-randomized arms implemented sequentially: (1) a single-session arm of healthy adults focused on acceptability, usability, and emotional safety; (2) a four-hour intervention arm of adults with DSM-5 diagnosed mental disorders in residential care; and (3) a four-hour intervention arm of healthy older adults aged 65 years and older. Quantitative outcomes assess affect, mental well-being, and recovery-related constructs. Additional measures include usability, satisfaction, and qualitative feedback. Ecological momentary assessment (EMA) is conducted in Arms 2 and 3.",[395,29,396,397,398],"Institutionalization","Mental Health","Wellbeing","Aging",[400,401,402,403,404,405,406,407,408,409,410,411,412,413],"artificial intelligence","digital mental health","human-computer interaction","recovery","identity","autobiographical narrative","life story","reminiscence","wellbeing","storytelling","residential care","older adults","chatbot intervention","mental health","2026-03-19",{"date":416,"type":37},"2026-03-27",{"date":418,"type":37},"2026-02-12",{"date":375,"type":22},{"name":421,"class":44},"Universitat Autonoma de Barcelona",{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":17,"minAge":303,"maxAge":270,"enrollmentInfo":430,"targetDuration":431,"studyType":134,"phases":4,"briefSummary":432,"conditions":433,"keywords":437,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":452},"100629782","senior-stroke-prevention-in-the-elderly-by-patent-foramen-ovale-closure-vs-anticoagulation-100629782","NCT07479147","SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation","Patent Foramen Ovale-Related Stroke Management and Outcome: Age-dependent Risk Prediction and Atrial Cardiopathy Study (SENIOR Study)","SENIOR","Inclusion Criteria:\n\n* Patient or his\u002Fher legal representative signs a written informed consent\n* Participants who have diagnosed as PFO related stroke\n* For patient aged 18-59: patient with high risk PFO feature or RoPE score ≥ 7\n* For patient aged 60-90: patient with high risk PFO feature or RoPE score ≥ 4, must include cortical infarct\n\nExclusion Criteria:\n\n* Follow-up less than 6 months\n* Extracardiac right-to-left shunt\n* Known stroke mechanism was diagnosed",{"count":56,"type":22},"3 Years","Patent foramen ovale (PFO) is an important mechanism of embolic stroke of undetermined source (ESUS). Current guidelines recommend PFO closure for high-risk PFO in patients younger than 60 years, and a recent retrospective cohort study from Taichung Veterans General Hospital has shown that closure is effective and safe in older adults; however, the optimal treatment strategy for those \\>60 years and direct head-to-head comparisons of PFO closure versus direct oral anticoagulants (DOACs) remain insufficient. Robust evidence from a multicenter study combining prospective and retrospective cohorts is warranted.\n\nThe SENIOR study is a multicenter observational cohort registry with a combined retrospective and prospective design. The prospective period is from September 15, 2025 to December 31, 2031, and the retrospective period covers January 1, 2013 to September 1, 2025; target sample sizes are 400 (prospective) and 500 (retrospective). We will enroll adults with ESUS and PFO; the prospective arm will focus on patients aged \\>60 years with PFO related stroke. Treatments will be assigned as PFO closure, standard-dose DOAC, or antiplatelet agents (if DOAC intolerance) by local principal investigator. The primary outcome is recurrent ischemic stroke or transient ischemic attack. Secondary outcomes include 6-month functional outcome, all stroke, and serial comparison of atrial cardiopathy changes. Safety endpoints include peri-procedural adverse events (including newly-onset atrial fibrillation), hemorrhagic stroke, and all caused mortality. Clinical presentation, imaging, cardiac testing, biomarker, and genetic data will be collected for stratified and multivariable analyses.",[434,435,436,29],"Ischemic Stroke","Embolic Stroke of Undetermined Source","Patent Foramen Ovale (PFO)",[438,439,440,71,441,442],"patent foramen ovale","patent foramen ovale closure","embolic stroke of undetermined source","multi-center","anticoagulation","2026-03-18",{"date":445,"type":37},"2026-03-23",{"date":447,"type":37},"2025-12-16",{"date":449,"type":22},"2031-12-31",{"name":451,"class":44},"Taichung Veterans General Hospital",3,{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":23,"phases":461,"briefSummary":462,"conditions":463,"keywords":467,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":472,"completionDateStruct":473,"leadSponsor":475,"locationsCount":45},"100629826","phase-4-anesthesia-maintenance-with-target-controlled-infusion-of-propofol-and-remifentanil-at-fixed-ratio-100629826","NCT07479719","Anesthesia Maintenance With Target-controlled Infusion of Propofol and Remifentanil at Fixed Ratio","Anesthesia Maintenance With Target-controlled Infusion of Propofol and Remifentanil at Fixed Ratio on Neurocognitive Recovery in Older Patients After Surgery: a Randomized Trial","Inclusion Criteria:\n\n1. Aged ≥ 65 years.\n2. Scheduled to undergo noncardiac surgery expected to last ≥ 1 hour under general anesthesia.\n3. Require patient-controlled intravenous analgesia after surgery.\n4. Provide written informed consent.\n\nExclusion Criteria:\n\n1. Inability to communicate in the preoperative period because of coma, profound dementia, language barrier, or other reasons.\n2. Previous history of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis.\n3. Traumatic brain injury or neurosurgery.\n4. Severe hepatic dysfunction (Child-Pugh class C), severe renal dysfunction (eGFR \\\u003C30 ml\u002Fmin\u002F1.73 m2), or critical illness (preoperative American Society of Anesthesiologists physical status classification ≥IV).\n5. Planned ICU admission with endotracheal intubation after surgery.\n6. Enrolled in the other studies.\n7. Other reasons that are considered unsuitable for study participation by the responsible surgeons or investigators.",{"count":160,"type":22},[274],"The impact of anesthesia depths on early postoperative neurocognitive complications after total intravenous anesthesia (TIVA) remains controversial. In some studies investigating TIVA, anesthesiologists mainly achieve the target depth of anesthesia by adjusting the dose of propofol, whereas the doses of opioids remains comparable between different anesthetic depth groups, possibly resulting inadequate analgesia. This study is aimed to investigate the impact of different anesthesia depths maintained by target-controlled infusion of propofol and remifentanil at a fixed ratio on the incidence of early postoperative neurocognitive complications in older patients undergoing noncardiac surgery.",[29,464,465,466,278],"Surgery","Depth of Anesthesia","Total Intravenous Anesthesia",[29,464,468,469,284],"Depth of anesthesia","Total intravenous anesthesia","2026-03-15",{"date":443,"type":37},{"date":236,"type":22},{"date":474,"type":22},"2027-01",{"name":293,"class":44},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":482,"eligibilityCriteria":483,"healthyVolunteers":12,"sex":17,"minAge":304,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":486,"conditions":487,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":495,"leadSponsor":497,"locationsCount":45},"100629497","prognostic-factors-of-hospitalization-for-patients-aged-75-and-over-in-emergency-department-in-france---monocentric-retrospective-cohort-study-100629497","NCT07475442","Prognostic Factors of Hospitalization for Patients Aged 75 and Over in Emergency Department in France - Monocentric Retrospective Cohort Study","Prognostic Factors of Hospitalization for Patients Aged 75 and Over in Emergency Department in France - Monocentric Retrospective Cohort Study - PROFACTHOS","PROFACTHOS","Inclusion Criteria:\n\n* Adult over or equal 75 years old\n* Patient admitted to the emergency department between 10\u002F01\u002F2022 and 09\u002F30\u002F2023 for the second group, and between 10\u002F01\u002F2024 and 09\u002F30\u002F2025 for the first group\n* Patient and\u002For family and\u002For trusteeship who doesn't refused to participate\n\nExclusion Criteria:\n\n* Patient died before admitted to emergency department\n* Patient already included in the study\n* File created by mistake, identified by the mention \"Erreur de dossier\"\n* Patient deprived of total or partial liberty by a judicial or administrative decision",{"count":485,"type":22},967,"A geriatric patient is defined as a patient aged 75 and over who meets certain medical or social vulnerability criteria and is characterised by coexisting physical and\u002For psychological dependence. The proportion of patients with a geriatric profile in the general population is growing. The average time spent in the emergency department by the elderly population is about 3 hours longer than for patients under 75 years old in France, which is associated with the risk of decompensation of chronic conditions, confusion, falls or agitation. An overnight stay in the emergency department for these patients increases the risk of mortality and the length of hospital stay.\n\nSeveral prognostic scores for hospitalization have been studied in adult populations. The most widely used scores are the Sydney Triage to Admission Risk Tool (START), the Ambulatory (AMB) and the Glasgow Admission Prediction Score (GAPS). Studies have compared these three scores and demonstrated the greater robustness of GAPS. The CalcuLation of the Elderly Admission Risk in the Emergency Department (CLEARED) tool, developed for the elderly population, has lower performance than GAPS. A systematic review of the literature studied the power of GAPS for the geriatric population and highlighted the need for validation in the target population. No validated hospitalization prognostic score was found in France for this population. The research hypothesis is that GAPS would detect hight probability of admission at the time of triage for the patients aged 75 and over in emergency department in France. The primary objective of this monocentric study is to evaluate the prognostic performance of GAPS for the target population (on the group 1). The secondary objectives consist of developing and internally validating a new score (PROFACTHOS) (on the group 2), then performing a temporal validation of PROFACTHOS with comparison to the GAPS (on the group 1), and finally to determine the threshold for classifying patients with a high probability of hospitalization for the score with the strongest discriminatory performance among GAPS or PROFACTHOS.\n\nGroup 1: Patients aged 75 and over admitted to emergency department from 10\u002F01\u002F2024 to 09\u002F30\u002F2025.\n\nGroup 2 : Patients aged 75 and over admitted to emergency department from 10\u002F01\u002F2022 to 09\u002F30\u002F2023",[29,488,489,490],"Emergency Departments","Prognostic Factors","Hospitalizations","2026-03-10",{"date":493,"type":37},"2026-03-16",{"date":470,"type":22},{"date":496,"type":22},"2027-04-15",{"name":498,"class":44},"Poitiers University Hospital",{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":23,"phases":508,"briefSummary":509,"conditions":510,"keywords":512,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":522,"locationsCount":45},"100568086","estimate-the-safety-and-effectiveness-of-adjuvanted-influenza-vaccine-among-asian-elderly-people-when-compared-to-non-adjuvanted-vaccines-100568086","NCT06676644","Estimate the Safety and Effectiveness of Adjuvanted Influenza Vaccine Among Asian Elderly People When Compared to Non-adjuvanted Vaccines","A Comparative Study on the Immunogenicity and Safety of Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in the Elderly","influenza","Inclusion Criteria:\n\n* Adults aged 65 years or above\n* Presence of at least 1 chronic medical condition associated with increased risk of complicated influenza, including hypertension, chronic obstructive pulmonary disease (group A, B, E), asthma, congestive heart failure (ACC\u002FAHA stage A, B, C, D), coronary arterial disease, diabetes mellitus, chronic liver disease (Child-Pugh score A, B, C) or chronic kidney disease (stage 1\\~4), neuromuscular disorders, hematological or solid organ malignancies, recipient of hematopoietic stem cell transplantation or solid organ transplantation.\n\nExclusion Criteria:\n\n* Contraindications to influenza vaccination including history of severe adverse event after vaccination, such as anaphylaxis or Guillain-Barré Syndrome, or a severe bleeding tendency\n* Prior receipt of influenza vaccination during the current flu season.\n* Determination by the Principal Investigator (PI) that the participant is ineligible for enrollment based on clinical assessment.",{"count":160,"type":22},[25],"To compare the immunogenicity, cellular immune response, and safety between adjuvanted (aIIV4) and non-adjuvanted (IIV4) seasonal influenza vaccines in the Taiwanese elderly population with chronic medical conditions.",[511,29],"Influenza Vaccines",[505,513,514,71,515],"adjuvanted vaccine","immunogenicity","safety","2026-02-22",{"date":518,"type":37},"2026-02-24",{"date":520,"type":37},"2024-11-21",{"date":119,"type":22},{"name":523,"class":44},"National Taiwan University Hospital",{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":530,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":17,"minAge":532,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":23,"phases":535,"briefSummary":536,"conditions":537,"keywords":540,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":45},"100625596","catheter-ablation-vs-conservative-care-in-elderly-patients-with-atrial-fibrillation-100625596","NCT07424690","Catheter Ablation vs Conservative Care in Elderly Patients With Atrial Fibrillation","Assessment of the Effect of Catheter Ablation on Elderly Population With Atrial Fibrillation; a Randomized Controlled Study; The ACE-AF Study","ACE-AF","Inclusion Criteria:\n\n1. Age ≥78 years.\n2. ECG-documented atrial fibrillation.\n3. AF type: paroxysmal, persistent, or longstanding persistent AF.\n4. Suitable candidate for catheter ablation according to ESC guidelines.\n5. Charlson's comorbidity index ≤7.\n\nExclusion Criteria:\n\n1. Left atrial (LA) dimension \\>55 mm, based on echocardiography within the previous year.\n2. Acute coronary syndrome or coronary artery bypass surgery within the last 12 weeks.\n3. Severe valvular heart disease (per ESC definitions) or congenital heart disease.\n4. Prior surgical or catheter AF ablation procedure, or prior AV-node (atrioventricular nodal) ablation.\n5. Contraindication to oral anticoagulation.\n6. AF due to a reversible cause.\n7. Medical condition likely to limit survival to \\\u003C12 months.\n8. Unable or unwilling to provide informed consent.\n9. History of non-compliance with medical therapy.\n10. BMI \\\u003C18 or \\>37 kg\u002Fm².","78 Years",{"count":534,"type":22},282,[25],"ACE-AF is a multicenter randomized study in people aged 78 years and older with symptomatic atrial fibrillation (AF). AF is a common heart rhythm disorder in older adults and can cause reduced quality of life and lead to serious complications such as stroke and heart failure.\n\nThe study compares two established treatment strategies:\n\n1. Catheter ablation (an invasive procedure aimed at reducing AF by electrically isolating triggers in the heart, primarily through pulmonary vein isolation), and\n2. Optimized medical therapy without AF ablation (medications for rate and\u002For rhythm control; AV node ablation with pacemaker may be used if clinically indicated according to routine care).\n\nParticipants are randomized 1:1 to one of these strategies. All participants will receive an implantable loop recorder (a small heart rhythm monitor placed under the skin) to continuously track heart rhythm and measure AF burden over time.\n\nThe study has two co-primary outcomes assessed over 24 months:\n\n1. a composite of major clinical events (all-cause mortality, stroke, major bleeding, cardiac arrest, or hospitalization due to heart failure), and\n2. patient-reported health-related quality of life (HRQoL), measured by the SF-36 \"General Health\" domain.\n\nACE-AF will provide evidence to guide treatment decisions for very elderly patients with symptomatic AF and help identify which patients benefit most from an ablation-based strategy compared with optimized medical therapy.",[538,539,29],"Atrial Fibrillation (AF)","Atrial Fibrillation Ablation",[541,542,543,544,545,71,546,547],"atrial fibrillation","catheter ablation","rhtyhm control","rate control","implantable loop recorder","Health-related quality of life","Randomized controlled study","2026-02-14",{"date":550,"type":37},"2026-02-20",{"date":552,"type":22},"2026-05-20",{"date":554,"type":22},"2034-09-01",{"name":556,"class":44},"Karolinska University Hospital",{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":563,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":17,"minAge":304,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":23,"phases":566,"briefSummary":567,"conditions":568,"keywords":570,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":45},"100616773","feasibility-of-integrating-local-vibration-into-rehabilitation-of-elderly-patients-after-hip-fracture-100616773","NCT07309965","Feasibility of Integrating Local Vibration Into Rehabilitation of Elderly Patients After Hip Fracture","Feasibility Study on the Implementation of Local Muscle Vibration as Part of a Rehabilitation Program for Elderly Patients Following Fracture of the Upper End of the Femur","ORTHOBOOSTER-P","Inclusion Criteria:\n\n* Patients aged 75 or over who have undergone surgery for a fracture of the upper end of the femur\n* Hospitalised in the SMR department no later than D14 of their operation\n* Resource Iso Group greater than or equal to 3 on the Aggir scale\n* Patient capable of consenting who has signed a consent form or patient unable to express consent at the discretion of the principal investigator, informed and not opposed to the study, for whom a trusted person, or if not available, the family, or if not available, a close relative has signed an informed consent within a maximum of 2 days. For patients under guardianship, the guardian's consent will be requested, and for patients under curatorship, the patient will sign the consent in the presence of the curator within a maximum of 2 days as well.\n* Affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Persons deprived of their liberty by a judicial or administrative decision\n* Individuals with severe psycho-behavioral disorders (major psychiatric or neurocognitive disorders)\n* Persons admitted to a health or social establishment for purposes other than research\n* Contraindications to electrical stimulation:\n\n  * Patient with active devices such as pacemakers, defibrillators, insulin pumps, neurostimulators, etc\n  * Patient with phlebitis or risk of thrombosis\n  * Epileptic patient\n  * Patient with fragile skin or open wounds on the lower limbs\n* Subject participating in another interventional study with an exclusion period still in progress at pre-inclusion.",{"count":7,"type":22},[25],"Fractures of the upper end of the femur in elderly patients are the 2nd most common fracture.\n\nA fracture leads to a syndrome of psychomotor maladjustment, encouraged by pain and aggravated by hospitalisation. In 2014, 50,000 women and 16,000 men suffered this type of fracture every year. The consequences are serious, with a one-year mortality rate of 20 to 24% and an institutionalisation rate of 25%. In 2015, the direct cost of hip fracture in France was estimated at around €1 billion.\n\nIn line with the recommendations of the National Institute for Health and Care Excellence (NICE) and the results of meta-analyses, it is recommended that, in the absence of surgical or medical contraindications, patients should be assessed within 24 hours of hip fracture surgery, with a view to initiating early mobilisation and multidisciplinary rehabilitation.\n\nIt has been shown in healthy subjects that prolonged application of localised vibrations optimises nerve capacity, leading to an increase in maximum voluntary force.\n\nFor population of frail elderly post-operative patients, this localised vibration technique could accelerate and improve functional recovery, particularly in terms of muscle strength, joint mobility and pain. A reduction in muscle loss is hoped for, with benefits in terms of tolerance compared with neurostimulation.\n\nAs part of the implementation of the above-mentioned recommendations, the investigators wish to assess the quality of the integration of this technique, already in use in the department on an ad hoc basis, into the organisation of the department and of the patient's care pathway as a complement to the rehabilitation protocols, by identifying the obstacles and facilitating factors. The study will also provide the first estimates of the effect on muscle recovery.\n\nThe investigator hypothesise that this local vibration protocol can be integrated into the rehabilitation department's work schedule and into the patient's care pathway, and that it will be acceptable to both the patient and the nursing staff.",[569,29],"Fracture Femur",[571,572,573,574],"Rehabilitation","Fracture of the upper end of the femur","Local muscle vibration","Geriatrics","2026-02-05",{"date":577,"type":37},"2026-02-09",{"date":579,"type":37},"2025-11-19",{"date":581,"type":22},"2026-12-19",{"name":583,"class":44},"Hospices Civils de Lyon",{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":17,"minAge":87,"maxAge":304,"enrollmentInfo":591,"targetDuration":4,"studyType":23,"phases":593,"briefSummary":596,"conditions":597,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":605,"locationsCount":45},"100623386","phase-1-the-efficacy-and-safety-of-metformin-intervention-in-elderly-overweight-or-obesity-with-mild-cognitive-impairment-100623386","NCT07395960","The Efficacy and Safety of Metformin Intervention in Elderly Overweight or Obesity With Mild Cognitive Impairment","The Efficacy and Safety of Metformin Intervention in Elderly Overweight or Obesity With Mild Cognitive Impairment by a Single-center, Randomized, Placebo-controlled Interventional Study (Include Elderly Patients With Obesity or Overweight)","Inclusion Criteria:\n\n* Age: 60 - 75 years old\n* Body Mass Index: ≥ 24 kg\u002Fm2\n* Glycated Hemoglobin \\\u003C 8.5%\n* Moca Scale score: 20-26 points (education\\> 10 years) or 20-25 points (education≤ 10 years)\n* Sign the informed consent form\n\nExclusion Criteria:\n\n* Any hypoglycemic drugs have been used within 8 weeks prior to enrollment\n* Type 1 diabetes\n* Unable to undergo central nervous system magnetic resonance examination\n* History of alcohol or drug addiction\n* Severe gastrointestinal diseases, history of gastrointestinal surgery, severe cardiac or pulmonary dysfunction, malignant tumors and other diseases\n* Abnormal liver function (liver enzyme indicators more than 2.5 times the upper limit of the reference range) or abnormal kidney function (estimated glomerular filtration rate\\\u003C 45 ml\u002Fmin)\n* There are diseases such as cerebral infarction and vascular dementia\n* There are conditions judged by the investigator as being unsuitable for enrollment",{"count":592,"type":22},54,[594,595],"PHASE1","PHASE2","The prevalence of cognitive impairment in elderly obese patients is high, and the burden on families and society is heavy. Early intervention for mild cognitive impairment (MCI) is of great value. Central nervous system insulin resistance plays a role in the pathogenesis of cognitive impairment, and functional magnetic resonance imaging(fMRI) can evaluate cognitive impairment by observing central insulin resistance. Some large database studies of Type 2 Diabetes show that metformin is related to reducing the risk of dementia, but some studies have different conclusions, and there is few related study in elderly obese patients. The investigators speculate that metformin may improve cognitive dysfunction by improving central insulin resistance in elderly obese patients.\n\nA prospective, randomized controlled single center clinical cohort study will be conducted on 54 elderly obese patients with MCI. One group will receive metformin and lifestyle intervention, while the control group will receive simple lifestyle intervention. All subjects will be followed up for 26 weeks. Medical history collection, physical examination, and laboratory tests will be conducted before and after intervention, and the Montreal Cognitive Assessment Scale will be used for evaluation. Nasal insulin inhalation combined with fMRI will be used to evaluate central insulin resistance status as an objective basis for cognitive function evaluation. The main purpose of the study is to provide more accurate clinical research evidence for the prevention and treatment of MCI in elderly obese patients, in order to reduce the risk of developing dementia and alleviate the burden on families and society.",[598,599,29],"Mild Cognitive Impairment","Overweight or Obesity","2026-01-31",{"date":577,"type":37},{"date":603,"type":37},"2025-09-01",{"date":261,"type":22},{"name":606,"class":44},"Fudan University",{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":613,"eligibilityCriteria":614,"healthyVolunteers":12,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":615,"targetDuration":4,"studyType":23,"phases":617,"briefSummary":618,"conditions":619,"keywords":621,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":45},"100623309","hydration-guided-by-remote-dielectric-sensing-reds-system-for-preventing-acute-kidney-injury-in-elderly-patients-with-renal-insufficiency-for-coronary-angiography-and-intervention-100623309","NCT07394959","Hydration Guided by Remote Dielectric Sensing (ReDS) System for Preventing Acute Kidney Injury in Elderly Patients With Renal Insufficiency for Coronary Angiography and Intervention","Clinical Study on Tailored Hydration by Remote Dielectric Sensing System to Prevent Acute Renal Injury in Elderly Patients With Renal Insufficiency After Coronary Angiography","HISTORY","Inclusion Criteria:\n\n* Age ≥ 60 years;\n* Patients with unstable angina pectoris are scheduled for percutaneous coronary intervention；\n* Patients with chronic renal disease (estimated glomerular filtration rate \\\u003C 90 ml\u002Fmin);\n* Sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Acute decompensated severe heart failure or cardiogenic shock;\n* 2\\. Malignant tumors, severe renal failure (estimated glomerular filtration rate \\\u003C 30 ml\u002Fmin);\n* 3\\. Respiratory failure;\n* 4\\. Used contrast media within one week;\n* 5\\. Have allergic to contrast medium",{"count":616,"type":22},320,[25],"Explore the effectiveness and safety of tailored hydration guided by lung water index monitor system for prevention of acute kidney injury after percutaneous coronary intervention for elderly patients with renal insufficiency.",[28,620,29],"Chronic Kidney Disease",[622,623],"contrast induced acute kidney injury","acute pulmonary edema",{"date":625,"type":37},"2026-02-06",{"date":627,"type":37},"2024-09-20",{"date":629,"type":22},"2026-11-28",{"name":631,"class":44},"Chinese PLA General Hospital",{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":638,"eligibilityCriteria":639,"healthyVolunteers":130,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":640,"targetDuration":4,"studyType":23,"phases":642,"briefSummary":643,"conditions":644,"keywords":645,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":649,"lastUpdatePostDateStruct":650,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":655,"locationsCount":4},"100620573","progressive-resistance-exercise-versus-functional-training-in-elderly-with-risk-of-fall-100620573","NCT07359378","Progressive Resistance Exercise Versus Functional Training in Elderly With Risk of Fall.","Progressive Resistance Exercises Versus Functional Training in Elderly With Risk of Fall.","PRE","Inclusion Criteria:\n\n* Both Males and Female Patients\n* Patients Age 65 years or above\n* Participants with intact cognitive function or mild cognitive impairment who can follow instructions and provide informed consent\n* Individuals medically cleared by their physician to engage in moderate-intensity physical activities, with no unstable medical conditions that could impede participation\n* Participants willing to commit to an 8-week intervention program (3 sessions per week) and attend follow-ups as required.\n\nExclusion Criteria:\n\n* Elderly individuals who are non-ambulatory or unable to perform basic mobility tasks, such as standing or walking independently, even with assistive devices.\n* Uncontrolled medical conditions such as uncontrolled hypertension, unstable angina, or severe arrhythmias.\n* Participants with severe musculoskeletal conditions that significantly limit mobility or exercise participation (e.g., severe arthritis, recent fractures, or joint replacements within the last 6 months).\n* Presence of acute pain or injury that may worsen with physical activity. Individuals with progressive neurological conditions such as Parkinson's disease, 15 stroke with severe residual deficits, or multiple sclerosis that impede safe participation in physical activities.",{"count":641,"type":22},39,[25],"Study Design: Randomized Clinical Trial Objective: To find the effects of Progressive Resistance Exercises for balance and risk of falls in elderly population.\n\nTo find the effects of Functional Training for balance and risk of falls in elderly population.\n\nTo compare the effects of Progressive Resistance Exercises and Functional Training for balance and risk of falls in elderly population.\n\nInclusion Criteria:\n\nBoth Males and Female Patients Patients Age 65 years or above Participants with intact cognitive function or mild cognitive impairment who can follow instructions and provide informed consent Individuals medically cleared by their physician to engage in moderate-intensity physical activities, with no unstable medical conditions that could impede participation Participants willing to commit to an 8-week intervention program (3 sessions per week) and attend follow-ups as required.\n\nExclusion Criteria:\n\nElderly individuals who are non-ambulatory or unable to perform basic mobility tasks, such as standing or walking independently, even with assistive devices.\n\nUncontrolled medical conditions such as uncontrolled hypertension, unstable angina, or severe arrhythmias.\n\nParticipants with severe musculoskeletal conditions that significantly limit mobility or exercise participation (e.g., severe arthritis, recent fractures, or joint replacements within the last 6 months).\n\nPresence of acute pain or injury that may worsen with physical activity. Individuals with progressive neurological conditions such as Parkinson's disease, stroke with severe residual deficits, or multiple sclerosis that impede safe participation in physical activities.\n\nGroup 1: Progressive Resistance Exercises Participants in the Progressive Resistance Training (PRT) group will engage in a structured exercise program designed to progressively increase muscle strength, balance, and overall physical function.\n\nGroup 2: Functional Training Participants in the Functional Training (FT) group will engage in exercises that mimic daily activities to improve balance, strength, mobility, and functional independence.",[29],[646,647,648],"fall","progressive resistive","functional training","2026-01-29",{"date":651,"type":37},"2026-01-30",{"date":653,"type":22},"2026-01-01",{"date":491,"type":22},{"name":656,"class":44},"University of Lahore",{"id":658,"slug":659,"hasResults":12,"nctId":660,"briefTitle":661,"officialTitle":662,"acronym":663,"eligibilityCriteria":664,"healthyVolunteers":130,"sex":17,"minAge":303,"maxAge":665,"enrollmentInfo":666,"targetDuration":4,"studyType":23,"phases":668,"briefSummary":669,"conditions":670,"keywords":673,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":680,"lastUpdatePostDateStruct":681,"startDateStruct":683,"completionDateStruct":685,"leadSponsor":687,"locationsCount":294},"100620856","phase-2-a-study-to-evaluate-the-effects-of-the-combination-of-gi-102-with-gib-7-on-biomarkers-of-aging-in-healthy-adults-and-cancer-survivors-100620856","NCT07363057","A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors","Phase 2a, Proof-Of-Concept, Multi-National, 8-Week, Randomized, Single-Blinded, Placebo-Controlled Trial of GI-102 in Combination With GIB-7 to Evaluate Its Effects on Biomarkers of Aging in Healthy Adults and Cancer Survivors","GIANTS-1","Key Inclusion Criteria:\n\n1. Must be aged between ≥18 and ≤80 years old at the time of informed consent.\n2. At the discretion of the Investigator, must be in a state of general health that is not severely compromised (ie, no life-threatening illness or disability).\n3. Participants with a history of cancer may be included only if they meet one of the following:\n\n   1. Participants have been disease-free for ≥2 years; OR\n   2. For those diagnosed within 2 years:\n\n      * The cancer was treated with curative intent (eg, surgery, anti-cancer agents including chemotherapy)\n      * Participants have been in remission for ≥12 months\n      * Participants are not on any active cancer treatment except maintenance therapies (eg, endocrine therapy or bisphosphonates)\n      * Participants must have received systemic anti-cancer therapies without immunotherapy for their cancers\n4. Women of childbearing potential (WOCBP; see definition in Section 5.3) must agree to use a highly effective method of contraception from 14 days prior to Visit 2 until 180 days after the last dose of study medication (GI-102 or GIB-7). Fertile men must agree to use an acceptable method of contraception from 14 days prior to Visit 2 until 90 days after the last dose of study medication (GI-102 or GIB-7).\n\nKey Exclusion Criteria:\n\n1. Severe and poorly managed chronic diseases, such as advanced cardiovascular disease, kidney failure requiring transplant or dialysis, uncontrolled diabetes, detectable malignancy (≤ 2 years), severe chronic obstructive pulmonary disease (COPD), or untreatable, terminal cancer as judged by the Investigator or history of life threatening infection (eg, meningitis).\n2. Dependent on walkers or wheelchairs; severe difficulty or inability to perform activities of daily living independently or inability to perform study measures required to test muscle function (an amputee is eligible if participants can walk without walkers or wheelchair) as judged by the Investigator.\n3. Major surgery within the past 6 months or scheduled during the study period, including severe orthopedic diseases requiring joint replacement surgery.\n4. History of substance abuse or dependency or history of recreational IV drug use over the last 5 years (by self-declaration).\n5. Female participants who are pregnant, planning to become pregnant, or breastfeeding during the study period. Participants undergoing perimenopause or the menopause transition are eligible.","80 Years",{"count":667,"type":22},15,[595],"This Phase 2a clinical study (GIANTS-1) aims to evaluate a novel dual-combination strategy using GI-102 and GIB-7 to address key pathological features of aging, including immunosenescence (the aging of the immune system), metabolic dysfunction, and gut-brain-muscle axis dysregulation.",[671,672,29],"Cancer Survivors","Healthy Participant",[674,675,676,677,678,679],"GI-102","GIB-7","aging","immunosenescence","gut-brain-muscle axis dysregulation","metabolic dysfunction","2026-01-23",{"date":682,"type":37},"2026-01-26",{"date":684,"type":22},"2026-01",{"date":686,"type":22},"2026-10-01",{"name":688,"class":689},"GI Innovation, Inc.","INDUSTRY",{"id":691,"slug":692,"hasResults":12,"nctId":693,"briefTitle":694,"officialTitle":694,"acronym":695,"eligibilityCriteria":696,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":697,"targetDuration":4,"studyType":23,"phases":699,"briefSummary":700,"conditions":701,"keywords":705,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":709,"lastUpdatePostDateStruct":710,"startDateStruct":712,"completionDateStruct":714,"leadSponsor":716,"locationsCount":45},"100595301","early-discontinuation-of-antibiotic-therapy-in-elderly-patients-hospitalized-for-a-viral-infection-100595301","NCT07030673","Early Discontinuation of Antibiotic Therapy in Elderly Patients Hospitalized for a Viral Infection","ABUSIV","Inclusion Criteria:\n\n* Patients ≥ 65 years affiliated to a social security scheme\n* Hospitalized for a lower respiratory infection defined as:\n\n  * the presence of 2 of the following 4 signs:\n  * hyperthermia \\>38°C,\n  * hyperleukocytosis ≥12000 or ≤4000,\n  * purulent aspirations\u002Fsputum,\n  * rales on pulmonary auscultation indicating parenchymal damage\n  * associated with a pulmonary image (standard X-ray, CT scan or ultrasound)\n* Microbiological diagnostic sample taken within 48 hours\n* Informed consent of the patient or their representative\n\nExclusion Criteria:\n\n* Hospitalization planned for \\\u003C 48 hours or transfer planned to another center within 7 days\n\n  * Patient in septic shock,\n  * Febrile aplasia\n  * Absence of diagnostic microbiological sampling (\\> 48 hours after admission)\n  * Moribund patient,\n  * Death expected within the week\n  * Inhalation proven by endoscopy or eyewitness\n  * Purulent pleurisy, lung abscess, or other concomitant bacterial infection requiring antibiotic therapy.",{"count":698,"type":22},256,[25],"Among winter respiratory viruses, influenza is the most common and therefore responsible for the highest mortality, but parainfluenza and RSV viruses have an even higher risk of mortality (1.6 to 1.9 times), this toll being paid mainly by the elderly and co-morbid population. Futhermore, SARS-Cov2 will probably become endemic and\u002For epidemic with the same targets of fragile patients. These viral infections are serious, however a bacterial co-infection worsens the prognosis even more: excess risk of mortality = 2.6, 95% CI \\[1.9-3.7\\].\n\nAlthough rare, these co-infections are the subject of a prescription of antibiotics in more than 50% of influenza infections or other serious viral infections. Mainly due to this excess risk of mortality associated with the difficulty of diagnosing these co-infections.\n\nProper antibiotic use requires preventing this misuse and its harmful consequences in the short and long term at all costs. It is therefore imperative to have solid (grade A) evidence showing that antibiotic therapy in viral infections is not only futile but also potentially harmful.",[29,702,703,704],"Antibiotics Overuse","Viral Infections","PCR Multiplex",[706,71,707,708],"viral infections","antibiotics overuse","PCR multiplex","2026-01-15",{"date":711,"type":37},"2026-01-16",{"date":713,"type":37},"2025-02-14",{"date":715,"type":22},"2027-06",{"name":717,"class":44},"Centre Hospitalier Universitaire, Amiens"]